Yang Meng

2.2k total citations
47 papers, 1.5k citations indexed

About

Yang Meng is a scholar working on Epidemiology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Yang Meng has authored 47 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Epidemiology, 17 papers in Pathology and Forensic Medicine and 14 papers in Oncology. Recurrent topics in Yang Meng's work include Substance Abuse Treatment and Outcomes (14 papers), Alcohol Consumption and Health Effects (12 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Yang Meng is often cited by papers focused on Substance Abuse Treatment and Outcomes (14 papers), Alcohol Consumption and Health Effects (12 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Yang Meng collaborates with scholars based in United Kingdom, United States and China. Yang Meng's co-authors include Alan Brennan, Petra Meier, John Holmes, Daniel Hill‐McManus, Colin Angus, Robin C. Purshouse, S Harnan, Katy Cooper, Sue Ward and Lynda Wyld and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Yang Meng

43 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yang Meng United Kingdom	21	591	517	359	234	220	47	1.5k
Nora B. Henrikson United States	27	404 0.7×	274 0.5×	383 1.1×	396 1.7×	405 1.8×	93	2.3k
Christopher J. Johnson United States	25	618 1.0×	229 0.4×	230 0.6×	281 1.2×	265 1.2×	41	2.7k
Ronan W. Glynn Ireland	21	256 0.4×	182 0.4×	212 0.6×	307 1.3×	46 0.2×	44	1.6k
Lucy Elliss‐Brookes United Kingdom	17	559 0.9×	169 0.3×	219 0.6×	311 1.3×	258 1.2×	35	2.3k
Stephanie Melillo United States	15	331 0.6×	422 0.8×	386 1.1×	166 0.7×	164 0.7×	31	1.9k
Ned Calonge United States	20	196 0.3×	198 0.4×	199 0.6×	125 0.5×	179 0.8×	55	1.8k
Cheryll J. Cardinez United States	12	585 1.0×	298 0.6×	349 1.0×	335 1.4×	260 1.2×	15	2.8k
Sherri L. Stewart United States	27	267 0.5×	206 0.4×	201 0.6×	406 1.7×	144 0.7×	79	2.3k
Sandi L. Pruitt United States	31	701 1.2×	299 0.6×	481 1.3×	333 1.4×	273 1.2×	128	2.8k
Lewis E. Foxhall United States	15	415 0.7×	177 0.3×	144 0.4×	165 0.7×	63 0.3×	29	1.5k

Countries citing papers authored by Yang Meng

Since Specialization

Citations

This map shows the geographic impact of Yang Meng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yang Meng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yang Meng more than expected).

Fields of papers citing papers by Yang Meng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yang Meng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yang Meng. The network helps show where Yang Meng may publish in the future.

Co-authorship network of co-authors of Yang Meng

This figure shows the co-authorship network connecting the top 25 collaborators of Yang Meng. A scholar is included among the top collaborators of Yang Meng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yang Meng. Yang Meng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meng, Yang, et al.. (2024). Closed-loop transcutaneous auricular vagus nerve stimulation for the improvement of upper extremity motor function in stroke patients: a study protocol. Frontiers in Neurology. 15. 1379451–1379451. 4 indexed citations

Muston, Dominic, et al.. (2023). Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA. Targeted Oncology. 18(4). 531–541. 1 indexed citations

Meng, Yang, et al.. (2022). EE299 Budget Impact Analysis of Sentinel Prostate Test Versus Current Diagnostic Strategy for Men with Suspicion of Prostate Cancer in the US. Value in Health. 25(7). S392–S392. 1 indexed citations

Qu, Tingting, et al.. (2021). 1409P Cost-effectiveness of pembrolizumab plus platinum and fluoropyrimidine-based chemotherapy as first-line treatment of advanced esophageal cancer in the United States. Annals of Oncology. 32. S1059–S1060. 2 indexed citations

Zhong, Yichen, Haojie Li, Yang Meng, et al.. (2020). The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. Journal of Medical Economics. 23(9). 967–977. 16 indexed citations

Meng, Yang, et al.. (2020). Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1–positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States. Clinical Genitourinary Cancer. 19(1). e17–e30. 23 indexed citations

Bullement, Ash, et al.. (2018). A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?. Journal of Medical Economics. 22(3). 205–214. 22 indexed citations

Meng, Yang, Helen M. Johnson, Z Philips, et al.. (2018). The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. The European Journal of Health Economics. 19(8). 1163–1172. 20 indexed citations

Lee, Dawn, Javier Sabater, Helen M. Johnson, et al.. (2018). Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England. PharmacoEconomics - Open. 3(1). 43–54. 17 indexed citations

10.

Meng, Yang, et al.. (2017). Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours – an analysis based on the CLARINET study. Health and Quality of Life Outcomes. 15(1). 131–131. 14 indexed citations

11.

Meng, Yang, et al.. (2016). Cost Effectiveness of Nivolumab Monotherapy for the Treatment of Advanced Melanoma Patients in the United Kingdom. Value in Health. 19(7). A354–A354. 1 indexed citations

12.

Lee, Dawn, et al.. (2016). Cost Effectiveness of Nivolumab in Combination with Ipilimumab for the Treatment of Advanced Melanoma Patients in England. Value in Health. 19(7). A731–A731. 2 indexed citations

13.

Holmes, John, Yang Meng, Petra Meier, et al.. (2014). Effects of minimum unit pricing for alcohol on different income and socioeconomic groups: a modelling study. The Lancet. 383(9929). 1655–1664. 213 indexed citations

14.

Brennan, Alan, Yang Meng, John Holmes, Daniel Hill‐McManus, & Petra Meier. (2014). Potential benefits of minimum unit pricing for alcohol versus a ban on below cost selling in England 2014: modelling study. BMJ. 349(sep30 2). g5452–g5452. 40 indexed citations

15.

Brennan, Alan, Petra Meier, Robin C. Purshouse, et al.. (2013). Developing policy analytics for public health strategy and decisions—the Sheffield alcohol policy model framework. Annals of Operations Research. 236(1). 149–176. 19 indexed citations

16.

Hill‐McManus, Daniel, Colin Angus, Yang Meng, et al.. (2013). Estimation of usual occasion-based individual drinking patterns using diary survey data. Drug and Alcohol Dependence. 134. 136–143. 11 indexed citations

17.

Cooper, Katy, Yang Meng, S Harnan, et al.. (2011). Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation. Health Technology Assessment. 15(4). iii–iv, 1. 76 indexed citations

18.

Harnan, S, Katy Cooper, Yang Meng, et al.. (2011). Magnetic resonance for assessment of axillary lymph node status in early breast cancer: A systematic review and meta-analysis. European Journal of Surgical Oncology. 37(11). 928–936. 62 indexed citations

19.

Cooper, Katy, S Harnan, Yang Meng, et al.. (2011). Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: A systematic review and meta-analysis. European Journal of Surgical Oncology. 37(3). 187–198. 91 indexed citations

20.

Meng, Yang, Sue Ward, Katy Cooper, S Harnan, & Lynda Wyld. (2010). Cost-effectiveness of MRI and PET imaging for the evaluation of axillary lymph node metastases in early stage breast cancer. European Journal of Surgical Oncology. 37(1). 40–46. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact